Apollo Hospitals acquires IFC’s 3% share in Apollo Health and Lifestyle for Rs. 1,254 Cr
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Maria Soler Nunez appointed as Chief Quality Officer
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease
CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Subscribe To Our Newsletter & Stay Updated